---
schema_version: "secwatch.filing_event.v1"
accession: "0001785530-24-000018"
form_type: "8-K"
ticker: "HOWL"
cik: "0001785530"
company_name: "Werewolf Therapeutics, Inc."
filed_at: "2024-05-03T23:59:59+00:00"
generated_at: "2026-06-02T23:15:34.091195+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Werewolf Therapeutics reports Q1 net loss of $16.2M; cash runway extended to Q1 2026

## Summary
- Net loss $16.2M in Q1 2024, up from $12.0M loss in Q1 2023; R&D expenses rose to $12.9M.
- Cash and equivalents $139.2M at March 31, 2024; new $60M loan from K2 HealthVentures ($30M drawn) extends runway through Q1 2026.
- Collaboration revenue from Jazz Pharma fell to $0.7M from $4.5M YoY.
- Planned ASCO 2024 presentation of WTX-124 combination dose-escalation data; Q2 interim data for WTX-330 monotherapy.
- Preclinical advances: WTX-518 and WTX-712 show tumor regressions in mouse models; IL-10 for IBD presented at AAI.

## SEC filing metadata
- accession: 0001785530-24-000018
- form_type: 8-K
- ticker: HOWL
- cik: 0001785530
- company_name: Werewolf Therapeutics, Inc.
- filed_at: 2024-05-03T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1785530/000178553024000018/0001785530-24-000018-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1785530/000178553024000018/howl-20240503.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001785530-24-000018
- JSON: https://secwatch.observer/filing/0001785530-24-000018.json
- Plain text: https://secwatch.observer/filing/0001785530-24-000018.txt

## Key facts
- Earnings Releases
  Werewolf Therapeutics, Inc. reported first quarter ended March 31, 2024 results: revenue $0.7 million.
  - Period: first quarter ended March 31, 2024
  - Revenue: $0.7 million
  - Result: reported results
  source text: be sufficient to fund operational expenses and capital expenditure requirements through at least the first quarter of 2026. • Collaboration revenue: Collaboration revenue was $0.7 million for the first quarter of 2024, compared to $4.5 million for the same period in 2023. Collaboration revenue consists of revenue recognized from the Company’s licensing agreement
  evidence_url: https://www.sec.gov/Archives/edgar/data/1785530/000178553024000018/0001785530-24-000018-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.